Can risperidone (Risperdal) cause catatonia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Can Risperidone (Risperdal) Cause Catatonia?

Yes, risperidone can cause catatonia, though this is an uncommon but serious adverse effect that requires immediate recognition and intervention.

Understanding the Risk

While risperidone is primarily associated with extrapyramidal side effects (EPS), the development of catatonia represents a more severe neurological complication. The American Academy of Child and Adolescent Psychiatry guidelines acknowledge that differentiating between Parkinson-like side effects and "in severe cases, catatonia, may be difficult" when patients develop antidopaminergic symptoms 1. This diagnostic challenge is critical because the distinction directly impacts management decisions and patient outcomes.

Evidence of Risperidone-Induced Catatonia

Direct Case Reports

Multiple case reports document risperidone-induced catatonia:

  • A 61-year-old schizophrenic patient developed severe, dose-dependent catatonia on risperidone 5 mg daily, which immediately resolved upon switching to clozapine 2
  • A 21-year-old female developed malignant catatonia with stupor, catalepsy, negativism, and severe bronchorrhea after one week of risperidone, requiring ECT for resolution 3
  • A 16-year-old girl with early-onset schizophrenia developed acute catatonic symptoms during risperidone reintroduction 4

Drug Interaction Concerns

Risperidone combined with valproate appears particularly problematic:

  • A patient developed catatonia-like signs after a single dose of valproate while on risperidone and sertraline, which resolved with lorazepam but recurred with valproate re-challenge 5
  • A 23-year-old woman on risperidone 3 mg twice daily with valproate developed escalating somnolence, immobility, food refusal, and tremors—a catatonia-like presentation that resolved within 24 hours of switching to olanzapine 6

Clinical Context and Mechanism

Among atypical antipsychotics, risperidone has the highest propensity for extrapyramidal side effects 1. The FDA label confirms cases of EPS, neuroleptic malignant syndrome, and tardive dyskinesia in both adults and teenagers taking risperidone 7. The mechanism likely involves excessive dopamine blockade, particularly at higher doses or when combined with medications that increase risperidone levels (like valproate through pharmacokinetic interactions).

Systematic Review Findings

A 2025 systematic review of antipsychotics in catatonia treatment found that risperidone outcomes were "tended to be reported as beneficial" overall, but this included both treatment of pre-existing catatonia and cases where it may have contributed to the condition 8. Importantly, 10.9% of antipsychotic trials were harmful, and the review emphasized that non-beneficial outcomes occurred with all second-generation antipsychotics in varying proportions.

Critical Diagnostic Pitfall

The most dangerous clinical error is confusing risperidone-induced catatonia with neuroleptic malignant syndrome (NMS). Both can present with:

  • Rigidity and immobility
  • Altered mental status
  • Autonomic instability
  • Hyperthermia (though less consistent in catatonia)

The 2023 British Association for Psychopharmacology guidelines specifically address "antipsychotic-induced catatonia" as a distinct entity requiring special management 9.

Management Algorithm

When catatonia develops in a patient on risperidone:

  1. Immediately discontinue risperidone - This is non-negotiable given the dose-dependent nature observed in case reports 2

  2. Perform lorazepam challenge (1-2 mg IV/IM) - Rapid improvement within 30 minutes to 2 hours supports catatonia diagnosis and provides therapeutic benefit 6, 4, 5

  3. Rule out NMS - Check CPK, complete metabolic panel, CBC; assess for fever, severe rigidity, and autonomic instability

  4. If antipsychotic treatment must continue:

    • Switch to a lower-potency dopamine antagonist (olanzapine showed rapid resolution in one case 6)
    • Consider aripiprazole (partial dopamine agonist properties may be protective) 4
    • Avoid reintroducing risperidone

  5. If catatonia persists despite benzodiazepines: Consider ECT, which has demonstrated efficacy even in malignant catatonia with severe complications 3

Special Populations at Higher Risk

  • Children and adolescents: May be at higher risk for EPS than adults 1, and two pediatric cases of risperidone-induced catatonia are documented 4, 3
  • Patients on valproate: The combination appears particularly hazardous 6, 5
  • Patients with prior lobotomy or structural brain changes: May have altered susceptibility 2

Bottom Line for Clinical Practice

While risperidone-induced catatonia is uncommon, it is a documented, potentially severe adverse effect that can occur at therapeutic doses, particularly when combined with valproate. The condition is reversible with prompt recognition and discontinuation of risperidone. Any patient on risperidone who develops progressive immobility, mutism, or stupor requires immediate evaluation for catatonia versus NMS, with risperidone discontinuation as the first intervention while diagnostic workup proceeds.

References

3
Research

Malignant catatonia with severe bronchorrhea and its response to electroconvulsive therapy.

Progress in neuro-psychopharmacology & biological psychiatry, 2006

5
Research

Catatonia-like events after valproic acid with risperidone and sertraline.

Neuropsychiatry, neuropsychology, and behavioral neurology, 1998

8
Research

The use of antipsychotics in the treatment of catatonia: a systematic review.

European psychiatry : the journal of the Association of European Psychiatrists, 2025

Related Questions

Which medication, aripiprazole (Abilify) or risperidone (Risperdal), is associated with a lower incidence of catatonia?
In a young adult female with treatment‑resistant schizophrenia and catatonia, currently receiving lorazepam and aripiprazole 30 mg daily (Abilify Maintena injection), how should clozapine be initiated and titrated, including overlap with aripiprazole, and what hematologic, metabolic, cardiac, and sedation monitoring is required?
Are there any contraindications to hiatal hernia surgery in a patient with schizophrenia on aripiprazole (Abilify) and mirtazapine who has a history of catatonia?
Can selective serotonin reuptake inhibitors (SSRIs) cause catatonia?
Can aripiprazole (Abilify) cause catatonia?
Should blood glucose be checked on the day of surgery for a patient taking Farxiga (dapagliflozin)?
In a patient with accelerated hypertension and a heart rate of 72 bpm, can labetalol be administered?
A patient being treated with clindamycin for herpes zoster rash with bacterial superinfection develops diarrhea; what alternative antibiotic should be used?
How does an Achilles tendon injury present clinically?
How should labetalol be administered intravenously in an emergency setting?
What is the best practice for irrigating urinary catheters with extreme sediment buildup?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.